Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$73.70 USD

73.70
3,674,571

+0.40 (0.55%)

Updated Jul 18, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunomedics to be Acquired by Gilead for About 21 Billion

by Zacks Equity Research

Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $64.51 in the latest trading session, marking a +0.58% move from the prior day.

Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN

Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC

by Zacks Equity Research

Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.

Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas

by Zacks Equity Research

Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Gilead-HiFiBiO Ink Deal to Develop Antibodies Against Leukemia

by Zacks Equity Research

Gilead's (GILD) subsidiary, Kite, enters into a two-year research deal with HiFiBiOto develop antibodies against acute myeloid leukemia.

Ritujay Ghosh headshot

Vaccine Hopes Rise Again: 4 Stocks to Watch

by Ritujay Ghosh

The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).

Gilead Sciences (GILD) Stock Moves -1.32%: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $65.91, marking a -1.32% move from the previous day.

Sanofi, Glaxo Start Clinical Study on Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) and Glaxo have a collaboration to develop an adjuvant vaccine against coronavirus.

Gilead Inks Deal With Jounce to License an Oncology Candidate

by Zacks Equity Research

Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.

Sanofi's Kevzara Fails as a Potential COVID-19 Treatment

by Zacks Equity Research

Sanofi's (SNY) phase III study evaluating Kevzara in severely or critically ill patients hospitalized with COVID-19 fails to meet primary endpoint and key secondary endpoint.

Glaxo/Vir Biotech Begin Clinical Study on Coronavirus Therapy

by Zacks Equity Research

Glaxo (GSK) and Vir Biotechnology have a collaboration to develop antibody therapies for treating COVID-19.

Gilead's Veklury Gets FDA Nod for Expanded Use in Coronavirus

by Zacks Equity Research

Gilead's (GILD) Veklury can now be used to treat all hospitalized patients with COVID-19, in addition to severe COVID-19.

Gilead (GILD) Down 9.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $65.26 in the latest trading session, marking a -0.44% move from the prior day.

Biotech Industry Near-Term Outlook Modest Amid Coronavirus

by Zacks Equity Research

With the coronavirus outbreak refusing to subside anytime soon, biotech companies gain focus as they race against time to evaluate every possible therapy to break the chain.

Kinjel Shah headshot

FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus

by Kinjel Shah

Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.

Regeneron Gains on Coronavirus Treatment Development Efforts

by Zacks Equity Research

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.

Company News for Aug 20, 2020

by Zacks Equity Research

Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.

Regeneron, Roche to Distribute Antibody Cocktail for Coronavirus

by Zacks Equity Research

Regeneron (REGN) teams up with Roche to develop and distribute REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19.

Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug

by Zacks Equity Research

Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.

Gilead Expands Collaboration With Tango for Cancer Therapies

by Zacks Equity Research

Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.

Roche Gets FDA Nod for Nervous System Disorder Drug Enspryng

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for NMOSD drug under the brand name, Enspryng.